TY - JOUR
T1 - Aberrant Expression of Plastin-3 Via Copy Number Gain Induces the Epithelial–Mesenchymal Transition in Circulating Colorectal Cancer Cells
AU - Sugimachi, Keishi
AU - Yokobori, Takehiko
AU - Iinuma, Hisae
AU - Ueda, Masami
AU - Ueo, Hiroki
AU - Shinden, Yoshiaki
AU - Eguchi, Hidetoshi
AU - Sudo, Tomoya
AU - Suzuki, Akira
AU - Maehara, Yoshihiko
AU - Mori, Masaki
AU - Mimori, Koshi
N1 - Funding Information:
ACKNOWLEDGMENT The authors thank T. Shimooka, K. Ka-sagi, S. Kohno, T. Kawano, and M. Aoyagi for technical assistance. This work was supported in part by the following grants and foundations: CREST, Japan Science and Technology Agency (JST); Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, grant numbers 17109013, 18659384, 18390367, 18590333, 18015039, 19591509, 19390336, 20390360, 20591547, 20790961, 20659209, 20790960, and 24592005; the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) Grant-in-Aid for Scientific Research on Priority Areas, grant number 18015039; Third Term Comprehensive Ten-Year Strategy for Cancer Control, grant number 16271201; New Energy and Industrial Technology Development Organization (NEDO) Technological Development for Chromosome Analysis; MEXT of Japan for Scientific Research on Priority Areas, Cancer Translational Research Project, Japan.
Publisher Copyright:
© 2013, Society of Surgical Oncology.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Purpose: Plastin-3 (PLS3) is a novel marker for circulating tumor cells (CTCs) in colorectal cancer (CRC). We sought to investigate the mechanisms mediating the aberrant expression of PLS3, the role of PLS3 in the epithelial–mesenchymal transition (EMT), and its association with the acquisition of invasive and metastatic abilities in human CRC. Methods: The expression levels of PLS3 messenger RNA in the tumor drainage venous blood (TDB) were examined in 177 CRC cases, and the associations between PLS3 expression and Xq23 copy numbers were analyzed in 132 CRC samples. We then established a stable PLS3-expressing CRC cell line and assessed the role of PLS3 in the EMT. Results: In clinical CRC cases, high expression of PLS3 in CTCs of TDB as well as peripheral blood was established as an independent prognostic factor of overall survival (p < 0.001), and the copy number gain of Xq23, which is the locus of the PLS3 gene, was significantly related to PLS3 overexpression. PLS3 induced the EMT via transforming growth factor (TGF)-β signaling and resulted in the acquisition of invasive ability in CRC cells. Conclusions: The aberrant expression of PLS3 was associated with copy number gain in CTCs from primary tumors and was involved in the regulation of the EMT, contributing to a poor prognosis in CRC patients.
AB - Purpose: Plastin-3 (PLS3) is a novel marker for circulating tumor cells (CTCs) in colorectal cancer (CRC). We sought to investigate the mechanisms mediating the aberrant expression of PLS3, the role of PLS3 in the epithelial–mesenchymal transition (EMT), and its association with the acquisition of invasive and metastatic abilities in human CRC. Methods: The expression levels of PLS3 messenger RNA in the tumor drainage venous blood (TDB) were examined in 177 CRC cases, and the associations between PLS3 expression and Xq23 copy numbers were analyzed in 132 CRC samples. We then established a stable PLS3-expressing CRC cell line and assessed the role of PLS3 in the EMT. Results: In clinical CRC cases, high expression of PLS3 in CTCs of TDB as well as peripheral blood was established as an independent prognostic factor of overall survival (p < 0.001), and the copy number gain of Xq23, which is the locus of the PLS3 gene, was significantly related to PLS3 overexpression. PLS3 induced the EMT via transforming growth factor (TGF)-β signaling and resulted in the acquisition of invasive ability in CRC cells. Conclusions: The aberrant expression of PLS3 was associated with copy number gain in CTCs from primary tumors and was involved in the regulation of the EMT, contributing to a poor prognosis in CRC patients.
UR - http://www.scopus.com/inward/record.url?scp=84922841454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922841454&partnerID=8YFLogxK
U2 - 10.1245/s10434-013-3366-y
DO - 10.1245/s10434-013-3366-y
M3 - Article
C2 - 24217791
AN - SCOPUS:84922841454
SN - 1068-9265
VL - 21
SP - 3680
EP - 3690
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 11
ER -